-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

802.O1.6 802. Chemical Biology and Experimental Therapeutics: Novel Therapeutic Strategies for Hematologic Disorders: From Mechanistic to Preclinical Studies

Symposia: Chemical Biology and Experimental Therapeutics Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Sickle Cell Disease, Lymphoid Leukemias, ALL, Acute Myeloid Malignancies, AML, Combination therapy, MDS, Iron Deficiency, Translational Research, Plasma Cell Disorders, Genomics, Hemoglobinopathies, Chronic Myeloid Malignancies, Diseases, Immune mechanism, Treatment Considerations, Lymphoid Malignancies, Metabolism, Myeloid Malignancies, Biological Processes, Emerging technologies, Molecular biology, Technology and Procedures, Multi-systemic interactions, Pathogenesis
Saturday, December 7, 2024: 12:00 PM-1:30 PM
Room 33 (San Diego Convention Center)
Moderators:
Giulia Biancon, PhD, ARRAY(0xf0424dc) and Valeria Visconte, PhD, Taussig Cancer Institute
Disclosures:
No relevant conflicts of interest to declare.
12:00 PM

Amit K. Jaiswal, PhD1, Michelle L. Thaxton1*, Jacob Sorrentino2*, Georgia Scherer2*, Gunjan Sharma3*, Tasha L. Lin4, Tiffany M. Tran5*, Alexander J. Ritter6*, Robert Damoiseaux7*, Jeremy R. Sanford8*, Neil Garg9* and Dinesh S. Rao, MD, PhD1

1Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA
2University of California, Los Angeles
3University of California, Los Angeles, Los Angeles, CA
4Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, Los Angeles, CA
5Department of Medicine, University of California, Los Angeles, Los Angeles, CA
6Department of Molecular, Cellular and Developmental Biology and Center for Molecular Biology of RNA, University of California, Santa Cruz, Santa Cruz, CA
7MSSR, University of California, Los Angeles
8Center for Biomolecular Science & Engineering, University of California, Santa Cruz, Santa Cruz, CA
9University of California Los Angeles, Los Angeles

12:15 PM

Markus Meyerhöfer1,2*, Viral Shah2,3*, Aarón Gallego-Crespo, M.Sc.1,4*, Malte Andreas Behrendt, M.Sc.1,5*, Yawen Zhou, PhD4,6*, Maria Saura-Pañella4,6*, Björn Häupl, PhD7,8*, Thomas Kindler, MD1,4*, Matthias Theobald, MD5,6, Falk Butter, PhD9,10*, George S Vassiliou, MD, PhD11, Michael Kühn, MD1,5*, Brian J P Huntly, MD11*, Thomas Oellerich, MD4,8* and Daniel Sasca, MD4,6*

1Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
2German Cancer Consortium (DKTK), Frankfurt/Mainz, Germany, Mainz, Germany
3University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
4German Cancer Consortium (DKTK), Mainz / Frankfurt am Main, Germany
5German Cancer Consortium (DKTK), Frankfurt/Mainz, Mainz, Germany
6Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University, Mainz, Germany
7German Cancer Research Center (DKFZ), Heidelberg, Germany
8Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
9Institute of Molecular Biology, Mainz, Germany
10Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut,Greifswald, Greifswald, Germany
11Department of Haematology and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom

12:30 PM

Vera Adema, PhD1*, Giulia Faccincani, MS1*, Amy Cooper, PhD2*, Juan Jose Rodriguez-Sevilla, MD1*, Jieqing Chen2*, Natthakan Thongon, PhD1, Teresa Perry2*, Jennifer Tran2*, Fernando Alvarez2*, Zhijun Kang2*, Vijayan Ramaswamy2*, Roopa Thapar2*, Troy Johnson2*, Guillermo Garcia-Manero, MD1, Faika Mseeh2*, David Kummer2*, Philip Jones2*, Timothy Heffernan, PhD2* and Simona Colla, PhD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Institute for Applied Cancer Science (IACS), The University of Texas MD Anderson Cancer Center, Houston, TX

12:45 PM

Majd Al-Hamaly1*, Yelena Chernyavskaya1*, Meghan Haney, MD2*, Jeffery Jolly3*, Ronald Bruntz3* and Jessica Blackburn3*

1University of Kentucky, Lexington, KY
2Cincinnati Children's Hospital, Cincinnati, OH
3University of Kentucky, Lexington

1:00 PM

Michael P. Agius, PhD1*, Laura Hevenor2*, N Connor Payne, PhD3,4,5*, Qi Liu, PhD6*, Hyuk-Soo Seo, PhD7*, Romanos Sklavenitis-Pistofidis, MD2,8,9, Daniel Heilpern-Mallory2*, Puspalata Bashyal10*, Michelle P. Aranha, PhD2,8,9*, Elizabeth D. Lightbody, PhD2,8,9, Ralph Mazitschek, PhD4,5*, Sirano Dhe-Paganon, PhD11*, Jun Qi, PhD7* and Irene Ghobrial, MD2,8,9

1Dana Farber Cancer Institute, Boston, MA
2Dana-Farber Cancer Institute, Boston, MA
3Harvard T.H. Chan School of Public Health, Boston
4Center for Systems Biology, Massachusetts General Hospital, Boston, MA
5Department of Chemistry and Chemical Biology, Harvard Medical School/MGH, Boston, MA
6Department of Cancer Biology, Dana Farber Cancer Institute, Boston
7Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA
8Harvard Medical School, Boston, MA
9Broad Institute of MIT and Harvard, Cambridge, MA
10Dana Farber Cancer Institute, Boston
11Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA

1:15 PM

Xiaowu Dong, PhD1,2*, Yu Guo3*, Jingyu Zhang3*, Zheyuan Shen3*, Shuang Wu3*, Shuangshuang Geng3*, Xinna Ma1*, Miao Hu, MD, phd1 and Xinglu Zhou1*

1HealZen Therapeutics Co., Ltd, Hangzhou, China
2Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
3Hangzhou Institute of Innovative Medicine, Zhejiang University, Hangzhou, China

*signifies non-member of ASH